Clinical Trial

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-07-29; most recent amendment 2026-06-15.
Status change: Not Yet Recruiting → Recruiting 2025-09-19
Trial Details
NCT Number NCT07105111
Lead Sponsor Neurocrine Biosciences
Conditions Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Enrollment 50 participants
Start Date 2025-08-29
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-16